Spectral and Metra Biosystems to merge operations
This article was originally published in Clinica
In an attempt to add critical mass to two ailing small point-of-care diagnostics companies, Spectral Diagnostics and Metra Biosystems are to merge in a transaction which will result in annual sales of around $13 million and cash resources of more than $32 million. The transaction will end with Spectral holding 51% of the as yet unnamed new company and Metra controlling the remainder.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.